Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Faricimab - Roche

Drug Profile

Faricimab - Roche

Alternative Names: RG-7716; RO-6867461

Latest Information Update: 08 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Chugai Pharmaceutical; Roche
  • Class Bispecific antibodies; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Angiopoietin-2 inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Diabetic macular oedema; Wet age-related macular degeneration

Most Recent Events

  • 05 Mar 2019 Roche initiates enrolment in the phase III LUCERNE trial for Wet age-related macular degeneration (Treatment-naive) in USA (Intravitreous) (NCT03823300)
  • 22 Feb 2019 Phase-III clinical trials in Wet age-related macular degeneration (Treatment-naive) in USA (Intravitreous) (NCT03823287)
  • 30 Jan 2019 Roche plans the phase III LUCERNE trial for Wet age related macular degeneration (Treatment naive) in Australia, Austria, South Korea, Taiwan and the US (Intravitreous), in March 2019 (NCT03823300)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top